* ImmuLogic Pharmaceutical Corp., of Waltham, Mass., received a$5 million license payment from Marion Merrell Dow Inc. as part ofa 1992 agreement between the two firms to jointly develop andcommercialize ImmuLogic's allergy therapeutics. The $5 millionbrings the total in license and milestone payments received byImmuLogic to $24 million. Under the 1992 pact, payments couldeventually total up to $42 million.
* U.S. Bioscience Inc., of West Conshohocken, Pa., was granted aproduct license in France to market Ethyol, a selective cytoprotectiveagent. France is the fifth European country to grant approval.
* Diatech Inc., of Londonderry, N.H., received a grant from the U.S.Energy Department to support trials of Tin-117m-DTPA, aradiopharmaceutical therapeutic for the palliation of painful bonemetastases in cancer patients.
* Boston Scientific Corp., of Natick, Mass., renewed its researchagreement with St. Elizabeth's Hospital, of Brighton, Mass., in thefield of cardiovascular gene therapy.
(c) 1997 American Health Consultants. All rights reserved.